[HTML][HTML] Immunotherapy for non-small cell lung cancer: current landscape and future perspectives
Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of
patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective …
patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective …
[HTML][HTML] FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
Background Immune checkpoint inhibitor therapy has resulted in impressive and durable
clinical activity for many cancers including melanoma; however, there remain few reliable …
clinical activity for many cancers including melanoma; however, there remain few reliable …
Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics
RD Seban, JS Nemer, A Marabelle, R Yeh… - European journal of …, 2019 - Springer
Purpose An imaging-based stratification tool is needed to identify melanoma patients who
will benefit from anti Programmed Death-1 antibody (anti-PD1). We aimed at identifying …
will benefit from anti Programmed Death-1 antibody (anti-PD1). We aimed at identifying …
Perspectives on treatment of metastatic colorectal cancer with immune checkpoint inhibitor therapy
MA Morse, H Hochster, A Benson - The oncologist, 2020 - academic.oup.com
Despite lengthening survival, death rates from metastatic colorectal cancer (CRC) remain
unacceptably high, with a bright spot being the demonstration of durable responses in …
unacceptably high, with a bright spot being the demonstration of durable responses in …
[HTML][HTML] A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer
S Tietscher, J Wagner, T Anzeneder… - Nature …, 2023 - nature.com
Immune checkpoint therapy in breast cancer remains restricted to triple negative patients,
and long-term clinical benefit is rare. The primary aim of immune checkpoint blockade is to …
and long-term clinical benefit is rare. The primary aim of immune checkpoint blockade is to …
Nano-drug delivery systems for T cell-based immunotherapy
T cell-based immunotherapy, which tackles T cell dysfunction and exhaustion, offers broad
promising for treating cancer. Various T cell-based immunotherapies, such as immune …
promising for treating cancer. Various T cell-based immunotherapies, such as immune …
[HTML][HTML] Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor …
Background The success of agents that reverse T-cell inhibitory signals, such as anti-PD-
1/PD-L1 therapies, has reinvigorated cancer immunotherapy research. However, since only …
1/PD-L1 therapies, has reinvigorated cancer immunotherapy research. However, since only …
Immunotherapy discontinuation—how, and when? Data from melanoma as a paradigm
C Robert, A Marabelle, H Herrscher… - Nature reviews Clinical …, 2020 - nature.com
The optimal duration of therapy in patients receiving immune-checkpoint inhibitors (ICIs) is a
new but crucial question that has arisen owing to the observation of durable remissions in> …
new but crucial question that has arisen owing to the observation of durable remissions in> …
Metabolic regulation of the cancer-immunity cycle
LFS Patterson, SA Vardhana - Trends in immunology, 2021 - cell.com
The cancer-immunity cycle (CIC) comprises a series of events that are required for immune-
mediated control of tumor growth. Interruption of one or more steps of the CIC enables …
mediated control of tumor growth. Interruption of one or more steps of the CIC enables …
Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma
Rising global incidence, limited treatment options, and high lethality remain defining
characteristics of hepatocellular carcinoma (HCC).(1) Surgical and ablative treatments are …
characteristics of hepatocellular carcinoma (HCC).(1) Surgical and ablative treatments are …